On November 3, 2017 Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, reported that it will present two trials in progress posters at the 2017 SITC (Free SITC Whitepaper) annual meeting November 8-12, 2017 at the Gaylord National Hotel & Convention Center in National Harbor, Maryland, United States (Press release, Adaptimmune, NOV 3, 2017, View Source [SID1234521553]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In addition, Adaptimmune will have a corporate exhibition booth (#718), and the company will also be hosting a dinner for investors on November 10th with representatives from Adaptimmune’s leadership team and key opinion leader Dr. David S. Hong from The University of Texas MD Anderson Cancer Center. Please reach out to Adaptimmune Investor Relations ([email protected]) for more information on attending the dinner.

The trials in progress posters will summarize the study designs for Adaptimmune’s ongoing MAGE‑A4 multi‑tumor study in urothelial (“bladder”), melanoma, head and neck, ovarian, non-small cell lung cancer (NSCLC), esophageal, and gastric cancers; and, the combination study with NY-ESO and NY‑ESO and KEYTRUDA (pembrolizumab) in multiple myeloma Details are below.

Trials in Progress Posters:

Title: Study Design: Phase 1 dose escalation, multi-tumor study to assess safety, tolerability and antitumor activity of genetically engineered MAGE-A4 SPEAR T-cells in HLA-A2+ subjects with MAGE-A4+ tumors
– Poster Number: P247
– Session Time: November 10, 2017 from 12:30 PM to 2:00 PM (lunch) and 6:30 PM to 8:00 PM (reception)
– Location: Prince George’s Exhibition Hall DE

Title: Study Design: An Open-label Randomized Pilot Study of NY-ESO-1 SPEAR T-cells Alone or in Combination with Pembrolizumab in HLA-A2+ Subjects with Relapsed and Refractory Multiple Myeloma (NCT03168438)
– Poster Number: P248
– Session Time: November 11, 2017 from 12:30 PM to 2:00 PM (lunch) and 6:30 PM to 8:00 (reception)

Genocea Biosciences has filed a 10-Q – Quarterly report [Sections 13 or 15(d)] with the U.S. Securities and Exchange Commission (Filing, 10-Q, Genocea Biosciences, 2017, NOV 3, 2017, View Source [SID1234521559]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On November 3, 2017 X4 Pharmaceuticals, a clinical stage biotechnology company developing novel CXCR4 inhibitor drugs to improve immune cell trafficking to treat cancer and rare diseases, reported that the first data from its ongoing Phase 1b clinical study of X4P-001-IO in patients with melanoma will be presented at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) Annual Meeting on November 8-12 in National Harbor, MD (Press release, X4 Pharmaceuticals, NOV 3, 2017, View Source [SID1234521562]). A second poster highlighting the effects of CXCR4 inhibition in a syngeneic model of melanoma will also be presented.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The details of the poster presentations are as follows:

X4P-001, an Orally Bioavailable CXCR4 Antagonist, Increases T-cell Infiltration in Human Metastatic Melanoma
Friday, November 10, Abstract # P367, Session Category: Immune Modulation, Cytokines, and Antibodies

Efficacy and Mechanism of Action of CXCR4 Inhibition in B16-OVA Melanoma Model
Friday, November 10, Abstract # P356, Session Category: Immune Modulation, Cytokines, and Antibodies

About X4P-001-IO in Cancer

X4P-001-IO is an investigational selective, oral, small molecule inhibitor of CXCR4 (C-X-C receptor type 4) that regulates the tumor microenvironment, thereby enhancing endogenous anti-tumor responses. CXCR4 is a chemokine receptor that modulates immune function and angiogenesis through the trafficking of key immune cells such as T- cells, dendritic cells, and myeloid derived suppressor cells. CXCR4 signaling is disrupted in a broad range of cancers, facilitating tumor growth by allowing cancer cells to evade immune detection and creating a pro-tumor microenvironment. X4P-001-IO is being investigated in three separate clinical studies in solid tumors.

About Melanoma

Cutaneous malignant melanoma is the fifth most common cancer in men and the sixth most common cancer in women in the United States. When discovered early, melanoma is highly curable with 10-year overall survival rates approaching 95% for stage I melanoma and 45-77% for stage II melanoma.1 However, for patients with stage III and IV melanoma, the prognosis is much worse. The 10-year survival rate for stage IV melanoma is 10-15%.2 Adjuvant therapies for patients with resectable stage III melanoma include immunomodulating drugs, such as high dose interferon-α therapy and anti-CTLA-4 or PD-1 antibody therapy. Unmet medical needs remain to establish and improve overall survival in patients with advanced resectable melanoma, as well as improving objective response rates in patients who do not respond to existing treatments.

Cytokinetics has filed a 10-Q – Quarterly report [Sections 13 or 15(d)] with the U.S. Securities and Exchange Commission (Filing, 10-Q, Cytokinetics, 2017, NOV 3, 2017, View Source [SID1234521560]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Rexahn has filed a 10-Q – Quarterly report [Sections 13 or 15(d)] with the U.S. Securities and Exchange Commission (Filing, 10-Q, Rexahn, 2017, NOV 3, 2017, View Source [SID1234521561]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!